These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 22586316)
1. A new target for therapy in squamous cell carcinoma of the lung. Ohashi K; Pao W Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316 [TBL] [Abstract][Full Text] [Related]
2. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973 [TBL] [Abstract][Full Text] [Related]
3. Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer. Nicoś M; Powrózek T; Krawczyk P; Jarosz B; Pająk B; Sawicki M; Kucharczyk K; Trojanowski T; Milanowski J Med Oncol; 2014 Oct; 31(10):176. PubMed ID: 25173530 [TBL] [Abstract][Full Text] [Related]
5. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333 [TBL] [Abstract][Full Text] [Related]
6. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Ford CE; Lau SK; Zhu CQ; Andersson T; Tsao MS; Vogel WF Br J Cancer; 2007 Mar; 96(5):808-14. PubMed ID: 17299390 [TBL] [Abstract][Full Text] [Related]
7. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Terai H; Tan L; Beauchamp EM; Hatcher JM; Liu Q; Meyerson M; Gray NS; Hammerman PS ACS Chem Biol; 2015 Dec; 10(12):2687-96. PubMed ID: 26390252 [TBL] [Abstract][Full Text] [Related]
8. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. Miao L; Wang Y; Zhu S; Shi M; Li Y; Ding J; Yang J; Ye Q; Cai H; Zhang D; Liu H; Song Y BMC Cancer; 2014 May; 14():369. PubMed ID: 24885564 [TBL] [Abstract][Full Text] [Related]
9. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954 [TBL] [Abstract][Full Text] [Related]
10. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Pitini V; Arrigo C; Di Mirto C; Mondello P; Altavilla G Lung Cancer; 2013 Oct; 82(1):171-2. PubMed ID: 23932362 [TBL] [Abstract][Full Text] [Related]
11. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer]. Chen XX; Zhou CC Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756 [No Abstract] [Full Text] [Related]
12. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Iwai LK; Payne LS; Luczynski MT; Chang F; Xu H; Clinton RW; Paul A; Esposito EA; Gridley S; Leitinger B; Naegle KM; Huang PH Biochem J; 2013 Sep; 454(3):501-13. PubMed ID: 23822953 [TBL] [Abstract][Full Text] [Related]
13. Genetic insight and therapeutic targets in squamous-cell lung cancer. Sos ML; Thomas RK Oncogene; 2012 Nov; 31(46):4811-4. PubMed ID: 22266863 [TBL] [Abstract][Full Text] [Related]
14. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828 [TBL] [Abstract][Full Text] [Related]
16. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2. Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182 [TBL] [Abstract][Full Text] [Related]
17. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma. Park JW; Lee YS; Kim JS; Lee SK; Kim BH; Lee JA; Lee NO; Kim SH; Hong EK J Cancer Res Clin Oncol; 2015 Nov; 141(11):1973-83. PubMed ID: 25842034 [TBL] [Abstract][Full Text] [Related]
18. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis. Zhang S; Bu X; Zhao H; Yu J; Wang Y; Li D; Zhu C; Zhu T; Ren T; Liu X; Yao L; Su J J Pathol; 2014 Mar; 232(4):436-48. PubMed ID: 24293323 [TBL] [Abstract][Full Text] [Related]